Table 2.
Key second-order probabilistic lifetime outcomes per individual
| Outcome | Mean (95% CrI) outcome for aRBCX | Mean (95% CrI) outcome for mRBCX | Mean (95% CrI) incremental outcome |
|---|---|---|---|
| Adult-initiated individuals | |||
| Total costs (discounted) | £495,738 (£493,028 to £498,449) | £557,634 (£555,136 to £560,132) | − £61,895 (− £63,392 to − £60,399) |
| Total QALYs (discounted) | 9.38 (9.34 to 9.42) | 9.15 (9.11 to 9.19) | 0.24 (0.22 to 0.25) |
| ICER | – | – | aRBCX dominates mRBCX |
| Percentage of cost-saving PSA iterations | – | – | 100.0% |
| Percentage of QALY-increasing PSA iterations | – | – | 91% |
| Percentage of cost-effective PSA iterations | – | – | 100.0% |
| Total number of DMTs | 149.28 (148.70 to 149.86) | 293.20 (292.02 to 294.39) | − 143.92 (− 144.58 to − 143.27) |
| Total number of acute clinical events | 58.08 (56.92 to 59.24) | 71.41 (70.43 to 72.40) | − 13.33 (− 14.18 to − 12.49) |
| Total months spent on chelation therapy | 4.76 (4.74 to 4.77) | 36.50 (36.00 to 37.00) | − 31.75 (− 32.24 to − 31.25) |
| Total LYs (undiscounted) | 24.84 (24.74 to 24.93) | 24.43 (24.33 to 24.53) | 0.40 (0.37 to 0.43) |
| Paediatric-initiated individuals | |||
| Total costs (discounted) | £534,091 (£531,017 to £537,165) | £646,902 (£644,283 to £649,521) | − £112,811 (− £114,789 to − £110,833) |
| Total QALYs (discounted) | 16.04 (16.00 to 16.08) | 15.75 (15.71 to 15.80) | 0.29 (0.27 to 0.31) |
| ICER | – | – | aRBCX dominates mRBCX |
| Percentage of cost-saving PSA iterations | – | – | 100.0% |
| Percentage of QALY-increasing PSA iterations | – | – | 91.2% |
| Percentage of cost-effective PSA iterations | – | – | 100.0% |
| Total number of DMTs | 283.26 (282.22 to 284.3) | 557.01 (554.78 to 559.24) | − 273.75 (− 275.02 to − 272.48) |
| Total number of acute clinical events | 105.27 (103.39 to 107.16) | 129.20 (127.82 to 130.58) | − 23.93 (− 25.45 to − 22.40) |
| Total months spent on chelation therapy | 4.79 (4.78 to 4.81) | 67.92 (66.98 to 68.86) | − 63.13 (− 64.07 to − 62.19) |
| Total LYs (undiscounted) | 47.17 (46.99 to 47.34) | 46.42 (46.23 to 46.60) | 0.75 (0.70 to 0.80) |
aRBCX automated red blood cell exchange, CrI credible interval, DMT disease-modifying exchange transfusion, ICER incremental cost-effectiveness ratio, LY life year, mRBCX manual red blood cell exchange, PSA probabilistic sensitivity analysis, QALY quality-adjusted life year